Comparar métodos

	Índice de Qualidade de Vida em Dermatologia	Questionário de Impacto da Fibromialgia	Questionário de Doença de Parkinson-39
Área	Desfechos em saúde	Desfechos em saúde	Desfechos em saúde
Família	Process / pipeline	Process / pipeline	Process / pipeline
Ano de origem	1994	1991	1997
Autor original	Andrew Y. Finlay and Gul K. Khan	Cynthia S. Burckhardt et al.	Crispin Jenkinson et al.
Tipo	Self-report quality of life questionnaire	Self-report symptom and functional impairment questionnaire	Self-report quality of life questionnaire
Fonte seminal	Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210-216.	Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatic Diseases, 18(5), 728-735.	Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age and Ageing, 26(5), 353-357.
Outros nomes	DLQI, Finlay Index, Dermatology Quality of Life	FIQ, Fibromyalgia Impact, Fibromyalgia Questionnaire	PDQ-39, Parkinson's Disease Questionnaire, PDQ
Relacionados	3	4	4
Resumo	The DLQI is the primary patient-centered outcome measure in dermatology research and clinical practice. Developed by Andrew Finlay and Gul Khan in 1994, this 10-item self-report questionnaire quantifies the impact of skin disease on patients' daily functioning, emotional well-being, social relationships, and work capacity. It is simple, rapid, and applicable to virtually all dermatological conditions, making it the gold standard for assessing quality of life in dermatology.	The FIQ is the most widely used patient-reported outcome measure for fibromyalgia disease burden. Developed by Cynthia Burckhardt and colleagues in 1991, this 10-item questionnaire quantifies how fibromyalgia affects physical function, work capacity, depression, anxiety, sleep, pain, and fatigue. The revised version (FIQR, 21 items) offers enhanced psychometric properties and is the current standard in fibromyalgia clinical trials and practice.	The PDQ-39 is the most widely used patient-reported outcome measure for Parkinson's disease quality of life. Developed by Crispin Jenkinson and colleagues in 1997, this 39-item self-report questionnaire comprehensively assesses how Parkinson's symptoms affect daily functioning, emotional well-being, stigma, social support, and cognitive-communication abilities. It is the recommended instrument in major Parkinson's disease clinical trials and forms a core component of outcome measurement in movement disorders.